Clinical Trial Update: 18F-DTBZ for l Diagnosis of Parkinson's Disease and Monitoring the Severity of Disease by VMAT2 PET Imaging [Phase 2]

View source ↗

Summary

Phase 2 study using 18F-DTBZ VMAT2 PET imaging to diagnose Parkinson's disease and monitor disease severity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• 18F-DTBZ (fluorine-18 labeled dihydrotetrabenazine)

Snippet

Sponsor: Chang Gung Memorial Hospital | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED